Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Depreciation & Amortization (CF): 2009-2024

Historic Depreciation & Amortization (CF) for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to $1.5 million.

  • Gyre Therapeutics' Depreciation & Amortization (CF) rose 45.84% to $649,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 64.94%. This contributed to the annual value of $1.5 million for FY2024, which is 44.23% up from last year.
  • Per Gyre Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $1.5 million for FY2024, which was up 44.23% from $1.1 million recorded in FY2023.
  • Gyre Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $1.5 million during FY2024, with a 5-year trough of $138,000 in FY2020.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $1.1 million (2022), whereas its average is $1.2 million.
  • Per our database at Business Quant, Gyre Therapeutics' Depreciation & Amortization (CF) decreased by 5.48% in 2020 and then spiked by 274.83% in 2022.
  • Yearly analysis of 5 years shows Gyre Therapeutics' Depreciation & Amortization (CF) stood at $138,000 in 2020, then surged by 110.14% to $290,000 in 2021, then soared by 274.83% to $1.1 million in 2022, then dropped by 1.20% to $1.1 million in 2023, then surged by 44.23% to $1.5 million in 2024.